Background and Purpose-Subarachnoid hemorrhage (SAH) is a devastating form of stroke. Oxidative stress contributes to brain injury, but the mechanisms have been poorly studied. Here, we evaluated the role of 12/15-lipoxygenase (12/15-LOX), an enzyme known to cause cell death in ischemic stroke, on brain injury in a mouse model of SAH. Methods-C57Bl6 wild-type mice and Alox15 knockout mice were subjected to SAH using a direct blood injection technique.
A neurysmal subarachnoid hemorrhage (SAH) is a severe form of stroke, which often leads to death and disability. 1 Two phenomena lead to brain injury: early brain injury (EBI) and delayed cerebral ischemia, frequently associated with cerebral vasospasm. 2 EBI refers to the effect of transient global ischemia and toxicity of subarachnoid blood, causing apoptotic neuronal cell death through several mechanisms. 3 Mechanisms involved in EBI persist for several days, and neuroprotection against EBI has to be developed. 4 12/15-Lipoxygenase (12/15-LOX), an enzyme involved in the oxidative pathway, has been identified as a key target to prevent secondary brain injury after ischemic stroke. [5] [6] [7] Here, we evaluated the role of 12/15-LOX in EBI after SAH and the impact of a highly specific 12/15-LOX inhibitor, ML351. 
Methods
Data supporting the findings of this study are available from the corresponding authors on reasonable request. Detailed Materials and Methods are deposited in the online-only Data Supplement.
Animal experiments were performed following protocols approved by the MGH Institutional Animal Care and Use Committee in accordance with National Institutes of Health Guidelines. Briefly, SAH was induced in 11 Alox15 knockout mice and 80 genetically matched wild-type mice using an established direct blood injection technique. Intraperitoneal injection of the 12/15-LOX inhibitor ML351 (50 mg/kg) 8 or vehicle occurred 5 minutes after induction of SAH. Immunohistochemistry was assessed 1 and 3 days later; and brain edema, blood-brain barrier leakage, and functional outcomes were assessed 3 days later. The flowchart of the study is described in the Figure I in the online-only Data Supplement.
Results

12/15-LOX Is Overexpressed in Macrophages After SAH
Blood was directly injected into the chiasmatic cistern to establish SAH ( Figure 1A ). After sacrifice 1 day later, immunohistochemistry revealed that 12/15-LOX is overexpressed in SAH mice compared with sham-operated mice ( Figure 1B 
12/15-LOX Overexpression Increases Brain Injury After SAH
To investigate the impact of 12/15-LOX on brain injury, we induced SAH in Alox15 knockout mice, or injected the 12/15-LOX inhibitor ML351 to wild-type mice with SAH. 12/15-LOX expression remained slightly elevated in wildtype mice 3 days after SAH, which was reduced by ML351 treatment, whereas Alox15 knockout mice exhibited only background staining for 12/15-LOX ( Figure 1D ). Next, we detected widespread neuronal cell death surrounding the SAH area, as assessed by Fluorojade B staining in SAH mice, compared with Alox15 knockout mice and mice receiving ML351 (Figure 2A and 2B). Moreover, SAH mice developed cerebral edema, which was reduced in Alox15 knockout mice but not by ML351 ( Figure 2C ). We did not detect blood-brain barrier leakage in this model ( Figure 2D ), suggesting that edema in this model is mainly cytotoxic not vasogenic.
12/15-LOX Inhibition Improves the ShortTerm Functional Outcome After SAH
This model of SAH induces short-term neurological impairments. SAH-associated weight loss was reduced in Alox15 knockout mice ( Figure 3A) . Using a 4-point neuroscore, we found that the neurological deficit caused by SAH is decreased in mice receiving ML351 ( Figure 3B ). Little injury was detected using a modified Garcia scale ( Figure 3C ). Finally, spontaneous motor activity was decreased in SAH mice, which was reversed by ML351 and in Alox15 knockout mice ( Figure 3D ).
Discussion
In our study, 12/15-LOX was overexpressed in activated macrophages after SAH, and blocking 12/15-LOX activity decreased the level of brain injury and subsequently improved the short-term neurological outcome in mice.
This result is in line with previous studies evaluating the role of 12/15-LOX in ischemic stroke: 12/15-LOX is upregulated in the peri-infarct area in mice and humans, contributing to brain damage by causing both neuronal cell death and neurovascular injury. 5, 6 Surprisingly, 12/15-LOX is here increased predominantly in macrophages at 24 hours, rather than in neurons and endothelial cells; the injury mechanism may thus differ. Fewer 12/15-LOX positive cells are present at 72 hours. Considering the number of CD68+ cells after SAH is stable within the first 7 days after SAH, 9 this suggests its expression The role of oxidative stress in SAH has long been known. 10 Interestingly, baicalein administration in rats with SAH decreased EBI, notably because baicalein is a 12/15-LOX inhibitor. 11 Baicalein as a strong antioxidant is not specific; however, and data focusing strictly on 12/15-LOX were needed, particularly because the 12/15-LOX product 12-hydroxyeicosatetraenoic acid is elevated in the cerebrospinal fluid of SAH patients. 12 Our study has several limitations. First, our study only looked at short-term outcomes relevant to EBI and found fewer neurological deficits than previously; a possible impact of 12/15-LOX on cerebral vasospasm and delayed cerebral ischemia remains to be explored. Additionally, we have used male mice, and effects of 12/15-LOX in females remain to be determined. Moreover, future studies are needed to examine the mechanisms of 12/15-LOX injury in more detail, focusing on its activity in macrophages.
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